Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 18/20 | 1.00 |
| ▸ | RXRB | P28702 | 9/20 | 1.00 |
| ▸ | RXRG | P48443 | 9/20 | 1.00 |
| ▸ | RARB | P10826 | 6/20 | 1.00 |
| ▸ | RARG | P13631 | 6/20 | 1.00 |
| ▸ | RARA | P10276 | 5/20 | 1.00 |
| ▸ | PPARG | P37231 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.51 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.51 |
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
| ▸ | PGR | P06401 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.51 |
| ▸ | DRD1 | P21728 | 1/20 | 0.51 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29357483 | 1.00 | RXRA (1.00) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL29434832 | 1.00 | RXRA (1.00) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL13752425 | 0.90 | RXRA (0.82) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL14816552 | 0.89 | RXRA (0.80) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL20411355 | 0.88 | RXRA (0.78) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL1073361 | 0.87 | RXRA (0.77) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL6376581 | 0.86 | RXRA (0.76) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL21549712 | 0.85 | RXRA (0.74) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL6889517 | 0.85 | RXRA (0.73) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL14816543 | 0.83 | RXRA (0.71) | RXRARXRBRXRGRARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 819 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026104588-A1 | UROLITHIN COMBINATION | AMAZENTIS SA (CH) | 2026-05-21 | — | — | WO | claimed |
| US-12571046-B2 | Methods of detecting and treating multiple system atrophy | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2026-03-10 | — | — | US | claimed |
| WO-2025024484-A1 | COMPOSITIONS AND METHODS FOR TREATING BLOOD CANCER | DUKE UNIVERSITY (US) | 2025-01-30 | — | — | WO | claimed |
| US-20240426845-A1 | METHOD FOR DETECTING A LIPIDATED PROTEIN VIA FLUORESCENCE RESONANCE ENERGY TRANSFER (FRET) | BIOGEN MA INC. | 2024-12-26 | — | — | US | claimed |
| EP-4433824-A1 | METHOD FOR DETECTING A LIPIDATED PROTEIN VIA FLUORESCENCE RESONANCE ENERGY TRANSFER (FRET) | Biogen MA Inc. (US) | 2024-09-25 | — | — | EP | claimed |
| US-12070461-B2 | Methods and formulations for modulating Lyn kinase activity and treating related disorders | MELIOR PHARMACEUTICALS I, INC. (US) | 2024-08-27 | — | — | US | claimed |
| EP-4334436-A1 | METHOD FOR INDUCING HYPERTROPHIC MUSCLE FIBERS FOR INDUSTRIAL MEAT PRODUCTION | Yeda Research and Development Co. Ltd (IL) | 2024-03-13 | — | — | EP | claimed |
| US-20240074473-A1 | METHOD FOR INDUCING HYPERTROPHIC MUSCLE FIBERS FOR INDUSTRIAL MEAT PRODUCTION | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2024-03-07 | — | — | US | claimed |
| US-20230263821-A1 | Treatment Of Increased Lipid Levels With Sterol Regulatory Element Binding Transcription Factor 1 (SREBF1) Inhibitors | UNIVERSITY OF MARYLAND, BALTIMORE | 2023-08-24 | — | — | US | claimed |
| WO-2023091395-A1 | METHOD FOR DETECTING A LIPIDATED PROTEIN VIA FLUORESCENCE RESONANCE ENERGY TRANSFER (FRET) | BIOGEN MA INC. (US) | 2023-05-25 | — | — | WO | claimed |
| US-20030113281-A1 | Assay for identification of compounds that promote melanin production and retinoid-like compounds identified by said assay | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2003-06-19 | — | — | US | claimed |
| US-6333318-B1 | USED IN THERAPY; FOR DELIVERING RECOMBINANT PROTEINS INTO A VARIETY OF CELLS WITHIN A PATIENT | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2001-12-25 | — | — | US | claimed |
| US-6320074-B1 | IN VIVO MODULATION OF LIPID METABOLISM, SKIN-RELATED PROCESSES, AUTOIMMUNE DISEASES, FATTY ACID METABOLISM, MALIGNANT CELL DEVELOPMENT, PREMALIGNANT LESIONS, OR PROGRAMMED CELL DEATH | LIGAND PHARMACEUTICALS INCORPORATED | 2001-11-20 | — | — | US | claimed |
| US-6316404-B1 | TREATMENT OF NON-INSULIN-DEPENDENT DIABETES MELLITUS USING AN RXR AGONIST ALONE OR IN COMBINATION WITH A PPAR.GAMMA. AGONIST SUCH AS A THIAZOLIDINEDIONE COMPOUND. | LIGAND PHARMACEUTICALS INCORPORATED | 2001-11-13 | — | — | US | claimed |
| EP-0983991-A2 | Compounds having selectivity for retinoid x receptors | LIGAND PHARMACEUTICALS, INC. (US) | 2000-03-08 | — | — | EP | claimed |
| EP-0983992-A2 | Compounds having selectivity for retinoid x receptors | LIGAND PHARMACEUTICALS, INC. (US) | 2000-03-08 | — | — | EP | claimed |
| US-6028052-A | FOR INCREASING GLUCOSE UPTAKE IN ADIPOSE OR MUSCLE TISSUE, COMPRISING THE STEP OF ADMINISTERING TO SAID TISSUE A COMPOSITION COMPRISING A PHARMACEUTICALLY EFFECTIVE AMOUNT OF AN RXR AGONIST | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2000-02-22 | — | — | US | claimed |
| US-5972881-A | TREATING HYPERTRIGLYCERIDEMIA, NON-INSULIN-DEPENDENT DIABETES MELLITUS USING A RETINOID X RECEPTOR AGONIST ALONE OR IN COMBINATION WITH A PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1999-10-26 | — | — | US | claimed |
| EP-0637297-A1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS, INC. (US) | 1995-02-08 | — | — | EP | claimed |
| WO-1993021146-A1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1993-10-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12070461-B2 | Methods and formulations for modulating Lyn kinase activity and treating related disorders | LYN, FYN, LPL | RXRA 1211/4885RXRB 1241/4885RXRG 950/4885 |
| US-12571046-B2 | Methods of detecting and treating multiple system atrophy | SYNJ1, MYT1, SYNJ2 | RXRA 18/4885RXRB 10/4885RXRG 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.